View in Other Languages 
Sydney, April 29, 2009 (ABN Newswire) - Cardiac catheter manufacturer CathRx Limited (ASX:CXD)(PINK:CTHXF) today announced the John Hunter Hospital had joined its Australian clinical trial to gather data for Australian Therapeutic Goods Administration (TGA) approval for its quadrapolar and decapolar diagnostic catheters.
John Hunter Hospital is a leading teaching hospital and major cardiology and cardiac surgery centre. CathRx's Australian approval trial began at Westmead Hospital in Sydney in November 2008.
CathRx Chief Executive Officer Neil Anderson said that while the catheters had already been CE marked and are on sale in Europe, the Australian trial was being conducted to enable CathRx to file for Australian approvals.
The protocol at John Hunter Hospital calls for use of CathRx's diagnostic catheters undergoing electrophysiology procedures that require the use of diagnostic catheters. There will be an equal number of CathRx and control patients. The primary end-point is a confirmation of diagnostic capability.
About cardiac arrhythmias
Cardiac arrhythmia describes a group of increasingly common conditions where there is abnormal electrical activity in the heart. The beating of a normal heart is controlled by electrical impulses. When these impulses are uncoordinated the heart fails to function properly. This can result in complications ranging from fatigue to stroke and even death. More than 10 million people worldwide suffer from abnormal heart rhythms. A trial fibrillation is the most common form of arrhythmia and affects over 5 million people worldwide. Current drug therapies often fail to control the problem and can have side effects. Physicians worldwide are increasingly using cardiac catheters to diagnose and successfully treat arrhythmias.
John Hunter Hospital is a leading teaching hospital and major cardiology and cardiac surgery centre. CathRx's Australian approval trial began at Westmead Hospital in Sydney in November 2008.
CathRx Chief Executive Officer Neil Anderson said that while the catheters had already been CE marked and are on sale in Europe, the Australian trial was being conducted to enable CathRx to file for Australian approvals.
The protocol at John Hunter Hospital calls for use of CathRx's diagnostic catheters undergoing electrophysiology procedures that require the use of diagnostic catheters. There will be an equal number of CathRx and control patients. The primary end-point is a confirmation of diagnostic capability.
About cardiac arrhythmias
Cardiac arrhythmia describes a group of increasingly common conditions where there is abnormal electrical activity in the heart. The beating of a normal heart is controlled by electrical impulses. When these impulses are uncoordinated the heart fails to function properly. This can result in complications ranging from fatigue to stroke and even death. More than 10 million people worldwide suffer from abnormal heart rhythms. A trial fibrillation is the most common form of arrhythmia and affects over 5 million people worldwide. Current drug therapies often fail to control the problem and can have side effects. Physicians worldwide are increasingly using cardiac catheters to diagnose and successfully treat arrhythmias.
About Cathrx Ltd
CathRx is a medical device company which manufactures and sells advanced cardiac catheter systems for the treatment of cardiac arrhythmias. CathRx's proprietary diagnostic and therapeutic catheters are designed to give physicians the tools to successfully treat patients with speed, safety and precision. CathRx's first diagnostic products are now on sale in Europe.
|
||
|
 |
Related Companies |
>>>    Cathrx Ltd |
| |
Related Industry Topics: |
Medical Equipment | Health & Pharm General | |
| |
This Page Viewed: (Last 7 Days: 30) (Last 30 Days: 290) (Since Published: 17790) |
(39150)
Events & Exhibitions
|
Site Search
| ENGLISH All Languages |
AJAX UNION |
|||
|
|||
Companies in the News
ABN Newswire on iPhone/iPad
|
| Download from Apple |
Mobile Video TV
|
||
|
||
){kind=link}